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INTRODUCTION
Mycophenolate mofetil (MMF), the first pharmaceutical
prodrug of mycophenolic acid (MPA) that received approval
for human clinical use, has been utilised in solid organ
transplantation since 1995, particularly in kidney transplan-
tation. MMF launching occurred one hundred years after
MPA discovery as a fermentation product of Penicillium
Brevicompactum and related fungi in 18931. Since 2002,
MMF is the more frequent immunosuppressant used in solid
organ transplantation. In kidney transplantation the antime-
tabolite MMF assumed a very important role in immunosup-
pressive regimens, with 80% of end-stage renal patients recei-
ving MMF at hospital discharge after kidney transplantation
in EUA2. The other prodrug of MPA, the enteric coated my-
cophenolate sodium (EC-MPAS), has been introduced in
transplantation drug market in 2004. Clinical experience
with this formulation is significantly lower than MMF, both
in organ transplantation and other human autoimmune dise-
ases, so we focus this review on the clinical use of MMF in
kidney glomerular diseases other than kidney transplanta-
tion. 
There is clinical rationale in trying to profit from MMF
properties to treat or arrest the progression of many chronic
glomerular diseases. In fact MPA which selectively inhibits
B and T lymphocyte proliferation acts as a blocker of the
inosine monophosphate dehydrogenase enzyme of the de
novo purine synthesis and is characterized by other proper-
ties that support its use in glomerular diseases that progress
to ESRD. These mechanisms are the impairment of antigen
presentation by dendritic cells, the suppression of monocyte
recruitment and of the glycosylation of adhesion molecules,
the inhibition of vascular smooth muscle cell proliferation
and of cytokine induced nitric oxide production. Mycophe-
nolate mofetil has also demonstrated synergistic effects with
angiotensin II inhibitors (ACE or ARA) in retarding the pro-
gression of chronic renal diseases in experimental animal
models3,4. 
Although there is theoretical support to use MMF in chro-
nic glomerular diseases, we have to wait for the conclusion
of adequately powered long-term randomized and contro-
lled clinical trials before it should receive approval for the
treatment of chronic glomerular diseases. At present time,
MMF use for treatment of renal diseases other than kidney
transplantation is supported by evidence-based medicine.
This review intends to be a comprehensive summary of the
main MMF indications in chronic glomerular diseases based
on clinical and laboratorial evidence nowadays. MMF indi-
cations in different kind of glomerular diseases are presen-
ted in decrescent schedule, according to the strength of the
evidence of its benefit, as showed in schematic picture of fi-
gure 1. 
LUPUS NEPHRITIS
The immunosuppressive treatment of lupus nephritis (LN)
showed a significantly improvement in last decades due pri-
marily to cyclophosphamide (CYC) use, but it is still very far
from the ideal therapy. The high rate of complications asso-
ciated with CYC therapy including infection, malignant dise-
ase, gonadal failure and alopecia, make clinicians interested
in finding another less toxic alternatives. There is also con-
cern about cases of resistance to cytotoxic therapy and fre-
quent relapses of active nephritis that forces us to look for
another drug with a more favourable profile both on efficacy
and tolerability5. There is increasing evidence suggesting that
MMF could be this alternative, as we can see in further de-
monstration of MMF efficacy in some randomized and con-
trolled clinical trials on proliferative and membranous LN6-13.
Recent meta-analysis about this matter support an important
role for MMF in lupus nephritis14-16. Azathioprine (AZA), a
less toxic immunosuppressive drug is not a good alternative
to CYC for LN, especially as a remission induction therapy,
as recently confirmed by data of a controlled randomized cli-
nical trial conducted by Grootscholten G et al, with a follow-
up of 2 years17.
Proliferative Lupus Nephritis (Classes III and IV) 
REMISSION INDUCTION THERAPY
Standard therapy to proliferative LN (Classes III and IV)
based upon a series of randomized controlled trials at the
EUA National Institutes of Health (NIH), has been a regi-
men consisting of six monthly pulses of intravenous CYC
(0,5-1 g/m2) followed by subsequent trimestral intravenous
CYC pulses for two years. The combination of this regimen
with monthly intravenous metilprednisolone could contribu-
te to higher efficacy concerning long term renal outco-
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mes18,19. To obviate adverse toxic events with this standard
regimen, an European based multicenter prospective trial
was designed, the European-Lupus Nephritis trial. This cli-
nical trial provided relevant data that allows us to safely use
lower and shorter doses of CYC (fixed intravenous pulses of
500 mg every 2 weeks for a total of six doses followed by
oral azathioprine as maintenance therapy) to induce the re-
mission of proliferative LN, in particular in case of less se-
vere renal injury20. 
There are some important controlled prospective studies
conducted to evaluate the efficacy and tolerability of MMF
in induction therapy of proliferative LN that have been pu-
blished6-13. There are other several randomized controlled
clinical trials underway at the moment to clarify definitively
MMF role on the treatment of LN. Data of the already pu-
blished trials are heartening to support MMF use in induc-
tion remission of LN, in particular in case of less severe
renal injury. The most important limitations of these studies
are the selective population of Asiatic patients, the few num-
ber of patients in each arm of the studied groups and the
short follow-up. One of these trials, randomized, conducted
by Chan T et al, compared induction of remission of prolife-
rative lupus nephritis with MMF (2 g a day) to oral CYC
(2,5 mg/kg/d) for 6 months, both with oral prednisolone, in
a Chinese population of 42 patients. At 6 months and during
the maintenance therapy, those in the MMF group continued
on MMF with smaller doses (1 g/day) and those in CYC
group were switched to azathioprine (1,5 mg/kg/day)6. Data
have been evaluated and published first at 12 months of fo-
llow-up, then more recently at 63 months of follow-up, with
the same favourable results on renal outcomes10. The main
conclusion of this trial and its expansion analysis was that
MMF associated with prednisolone was as effective as a re-
gimen of CYC and prednisolone followed by AZA but less
toxic (less incidence of infection). 
Another prospective trial, controlled but not randomized,
published by Hu et al in 2002 about MMF use in induction
therapy of LN, compared 6 months of oral MMF (1-1,5
g/day) with pulses of intravenous CYC in 46 Chinese pa-
tients with diffuse proliferative LN, both groups receiving
supplemental steroid treatment7. The investigation lead the
authors to conclude that MMF was more effective than CYC
in controlling renal outcomes (reduction of proteinuria and
hematuria, immunologic parameters of lupus activity like
anti-DNAds and histologic signs of vascular injury in serial
renal biopsies) and less toxic (especially gastrointestinal
symptoms and infections). The nonrandomized nature of
this study and the short follow-up (6 months) preclude any
definitive conclusions. Other randomized controlled study
comparing pulse intravenous CYC versus oral MMF in the
induction therapy of proliferative LN was recently publis-
hed by Ong LM et al11. They studied 44 patients with 6
months of follow-up. The main conclusion of this trial was
that MMF at doses of 2 g/day in combination with steroids
was as effective induction therapy as monthly intravenous
CYC (0,75-1 g/m2), at least for moderately severe prolifera-
tive LN. Ginzler EM et al published data of the larger rando-
mized controlled trial comparing oral MMF to monthly in-
travenous pulses of CYC in remission induction of lupus
nephritis12. They studied a population of 140 patients with
LN at high risk for renal failure. Forty six percent of studied
patients were Afro-americans and 54% had diffuse prolife-
rative nephritis at renal histology. The main limitations of
this study was a short follow-up of 6 months, the fact that in
the CYC group steroid pulses were not used (the standard
therapy for severe LN) and finally, the fact that more than
half of all patients did not reached the end of the study. We
have also to assinalate that 27 of the 140 patients had pure
membranous lupus. In this trial, MMF therapy was more ef-
fective than intravenous CYC in inducing remissions of LN
and it was associated with less adverse events. At 6 months
of follow-up there was an absolute difference of 16,7 per-
centage points between the number of patients who achieve
complete remission on the MMF arm and those on the intra-
venous CYC arm (95% CI, p = 0,005). 
In summary, there are some controlled randomized trials that
support the option of MMF to induce remission in LN instead
of intravenous CYC, especially in case of less severe renal in-
jury. This was elegantly summarized by Stassen PM et al.21. In
cases with rapidly progressive nephritis and acute renal failure,
there are no definitive results to support MMF use and we must
choose CYC and steroid pulses. Waldman M in a recent, exce-
llent review about lupus nephritis treatment, suggests MMF
therapy to induce remission in proliferative lupus nephritis at
the same level of CYC, depending only of the severity of the
disease and on the rigourous surveillance of the therapy resis-
tance22. There are some recent data proving that MMF choice is
associated with fewer adverse events compared to CYC and to
better quality of life due to the reduced side-effects during
MMF treatment13. 
There are at least six larger and long term multicenter in-
ternational trials underway to study efficacy and tolerability
of MMF (or EC-MPA) as remission induction and mainte-
nance therapy in lupus nephritis (NIH study numbers NCT
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Figure 1. Chronic glomerulopathies in which MMF has been used with
benefit. Diseases where evidence supporting its use is stronger are pre-
ented in the lower levels. At the left side, levels of evidence and grades





















Proliferative (Classes III, IV) and Membranous (Class V)
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00425438, 00298506, 00204022, 00423098, 00371319 and
00377637). These prospective, controlled and randomized
trials including approximately 1,300 patients, will be conclu-
ded in the next decade, and would definitely clarify MMF ap-
proval for LN therapy. 
REMISSION MAINTENANCE THERAPY
There are a few trials dedicated to studying the ideal mainte-
nance regimen in LN. What defines an optimous maintenance
drug is its efficacy to avoid relapses associated with long term
good tolerability. MMF has a favourable side-effect profile, as
we can extrapolate from the organ transplantation trials. The
beneficial effect of MMF as an antiproliferative drug, able to
reduce vascular smooth muscle cells proliferation and to poten-
ciate angiotensin II blockers, makes this prodrug very promi-
sing as an maintenance drug in LN3. The same can be thought
about AZA although the comparison of this antimetabolite drug
in maintenance therapy of lupus nephritis with MMF therapy is
not yet well clarified. 
The reference controlled randomized study concerning
MMF use in maintenance therapy in lupus nephritis was pu-
blished in 2004 by Contreras G et al8. They studied 59 pa-
tients with lupus nephritis (12 in class III, 46 in class IV and 1
in class V) that received induction therapy consisting of 6
monthly pulses of CYC (0,5-1 g/m2) plus oral corticosteroids
and than were randomly assigned to one of three maintenance
therapies: quartely intravenous CYC (0,5-1 g/m2), oral AZA
(1-3 mg/kg/day) or MMF (0,5-3 g/day) for one to three years.
The results demonstrated that MMF and AZA groups showed
better results on patient and renal survival than the CYC
group. The relapse incidence was lower in MMF group com-
pared with CYC group. In this study AZA seems to be a safer
and effective long term maintenance therapy, in opposite with
data about its effects in induction phase of lupus nephritis the-
rapy17. 
There are some prospective studies that demonstrated that
MMF could be an useful alternative in the treatment of lupus
nephritis in patients with failure, intolerance or relapses after
treatment with CYC and steroids23,24. To clarify the primacy of
these two drugs, MMF or AZA, on the maintenance therapy
of proliferative LN, there is now underway a randomized,
controlled trial, started at 2001 and that will be completed in
2011. This study, designed MAINTAIN Nephritis trial (NIH
number NCT00204022) is expected to help us to conclude
about MMF efficacy versus AZA for maintenance therapy of
proliferative LN. 
MEMBRANOUS LUPUS NEPHRITIS (CLASS V)
Membranous LN is characterized by the presence of global
or segmental continuous granular subepithelial immune
deposits. Should we also find the presence of subendothe-
lial immune deposits, then a combined diagnosis of LN
class III or IV and V must be used, depending on their dis-
tribution (International Society of Nephrology/Renal Pat-
hology Society guidelines, 2003)25. The treatment of LN
with those characteristics should follow the recommenda-
tions of proliferative LN treatment. This is a clear change
in the way of categorizing this type of injury, as in the an-
cient WHO classification system the combined lesions
were classified as Vc or Vd and treated like pure membra-
nous nephritis25,26. 
If, however, the renal biopsy shows a pure membranous
feature (Class V LN), which is reported in 20% of the cases,
the treatment of this entity remains unclear nowdays. There
is anedoctal experience with all kinds of immunosuppressi-
ve and cytotoxic drugs in membranous LN, including cy-
closporine (CsA), AZA, CYC, MMF, associated or not with
corticosteroids (small uncontrolled series, retrospective stu-
dies, case reports)22,27-29. Data on MMF use in pure membra-
nous LN is restricted to the prospective study of Ginzler EM
mentioned before, in which 27 of the 140 patients had pure
membranous LN12. The analysis of this subgroup results
showed that MMF response was similar to intravenous
monthly CYC response. There is underway another contro-
lled randomized NIH study to investigate both MMF and ta-
crolimus drugs on the treatment of pure membranous LN
(NCT00404794).
The natural evolution of membranous LN is variable, and per-
haps, the less severe cases can be treated in a more conservative
way. Appel GB et al recommended that pure membranous lupus
nephritis should be treated according to proteinuria levels and
glomerular filtration rate. Patients with subnephrotic levels of
proteinuria and preserved glomerular filtration rate should be tre-
ated with a short course of CsA associated to low dose corticos-
teroids and to an inhibitor of the renin-angiotensin system and
statins. For nephrotic patients, and those with reduced glomeru-
lar filtration rate, the alternatives are either CsA, intravenous
monthly CYC, MMF or AZA22. 
In summary, about MMF use for LN treatment, we con-
clude that for maintenance MMF seems an effective and se-
cure option, although this statement is mainly based in one
randomized controlled study of 140 patients, including pa-
tients either with proliferative and membranous lesions12.
For induction therapy, in proliferative LN, there are more
controlled randomized studies designed to assigne MMF
primacy, but all of them with some kind of limitations: a
small number of studied patients, a high number of asiatic
patients, less severe renal disease. Nevertheless, based on
these studies results and beyond the limitations mentioned,
MMF seems to be an adequate alternative to intravenous
CYC for remission induction therapy (table I). As recom-
mended by Appel GB, we could use MMF as first choice
therapy in cases of lesser severity of renal disease and con-
cern about side effects of CYC, and then keeping to mono-
torize outcomes and drug response. In case of drug resistan-
ce we must quickly switch to CYC22. The role of other
biologic agents like rituximab in combination with MMF for
induction therapy and maintenance in patients with prolife-
rative LN, will be clarify by multi-center prospective rando-
mized trials currently underway (NCT00282347). 
IGA NEPHROPATHY 
Many advances in understanding the pathogenesis of IgA
nephropathy have occurred in the last years. Genetic factors
have been recognized that could explain certain familial
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cases (e.g. gene loci 6q22-23)30,31. The undergalactosylation
of IgA1 at the O-linked hinge region and its deposition in
the mesangium is one of the processes best known, although
the primary defect (B cell or galactosyltransferase enzyme
defect) are not clearly defined32. 20-30% of patients with
idiopathic IgA nephropathy will develop end-stage renal fai-
lure at 20 years. The main predictors of poor outcome are
male gender, hypertension, persistent microscopic hematu-
ria and the extent of proteinuria and renal insufficiency33.
Specific treatment must be offered to those at risk for renal
failure. 
Standard therapy of IgA nephropathy in patients with predic-
tors of poor outcome is the use of angiotensin blockade (ACE in-
hibitors and/or angiotensin receptor blockers ARB) with the aim
of lowering blood pressure to values approximately of 110/70
mmHg and proteinuria of lower than 500 mg/day32-34. 
Immunosuppressive agents should be used when the res-
ponse to angiotensin blockers is not satisfactory33,35. Glucocor-
ticoids have been largely studied in IgA nephropathy and are
still a valid therapeutic option to reduce the risk for ESRD and
proteinuria even when used only for 6 months36,37. The primary
indication of steroids are the group of relatively well-preser-
ved renal function (creatinine clearance > 70 ml/m) and mode-
rate degree of proteinuria. Cytotoxic agents have also demons-
trated efficacy in these cases but with more adverse events.
The role of MMF in IgA nephropathy is not clearly stablished
as the results of published studies are contradictory38-41. Alt-
hough those trials are prospective, controlled and randomized,
studies lack sufficient statistic power as few patients reached
primary end-points. Two of them studied patients with mode-
rate to advanced IgA nephropathy and compared MMF the-
rapy with placebo in a total of 38 patients, did not show signi-
ficant benefit of MMF in reducing proteinuria or preserving
renal function39,41. The other two studies reported a total of 77
asiatic patients (chinese) and compare MMF to placebo or
prednisone. There was a significant reduction in proteinuria in
the MMF groups but without beneficial effect on renal insuffi-
ciency38,40. Follow-up in both of these studies was short, betwe-
en 6 and 12 months. 
There is currently underway at least 2 larger prospective
randomized trials designed to clarify MMF role on IgA neph-
ropathy treatment (NHI study number NCT 00318474 recrui-
ting 200 patients and Dal Canton et al’ study42). 
In table 1 we hereby present a summary overview of the
main clinical results of MMF use in the two groups of glome-
rular pathologies were randomized trials have been perfor-
med: Lupus nephritis and IgA Nephropathy.
ANCA-POSITIVE VASCULITIS 
ANCA-positive small vessel vasculitis included Wegener
Granulomatosis, ANCA positive Churg-Strauss syndrome,
microscopic polyangiitis and renal-limited small vessel
vasculitis. These entities represent 7-8% of the total popu-
lation of small-vessel vasculitis (systemic and renal limi-
ted) and are responsible for approximately 5% of cases of
ESRD43. Aggressive therapy of these disorders with kidney
involvement is absolutely determinant on the recovery of
renal function, and frequently associated with pulmonary
injury. The treatment is divided in two primary clinical is-
sues: remission induction and maintenance therapy.
REMISSION INDUCTION THERAPY
Standard remission therapy in ANCA-positive small vessel
vasculitis is intravenous pulses of methilprednisolone follo-
wed by CYC plus oral steroids. In dialysis-dependent patients
and patients with pulmonary injury, plasmapheresis may be
used instead of pulse intravenous methilprednisolone to indu-
ce remission of ANCA-positive small vessel vasculitis44. Con-
troversy about use of intravenous pulses of CYC or on oppo-
site oral CYC, was clarified by data from de Groot et al and
the European Vasculitis Study Group (EUVAS) that compa-
red intravenous CYC to oral CYC for induction of remission
in ANCA positive vasculitis in a randomized trial (CY-
CLOPS); they concluded that, there was no significant diffe-
rence of disease-free interval between the two groups and,
therefore, there seems to be little benefit to recommend oral
CYC as long term therapy45,46. 
Cyclophosphamide therapy, either intravenous or oral, is
not devoid of toxicity (35% of cases reporting severe adverse
events) as well of insufficient response (30% relapse inci-
dence); therefore, it’s reasonable to find alternative drugs47.
Methotrexate (MTX) is also being used during both induc-
tion and maintenance therapy phases of these forms of vas-
culitis but it’s a drug with non negligible profile of toxi-
city45,48. There are anedoctal reports of success with the use of
biologic agents like TNF blockers (infliximab) or the lymp-
hocyte-depleting drugs (anti CD52 mAb and anti CD20
mAb) in refractory disease but the high risk of cancer and
other serious adverse events associated with these therapies,
dissuade us to continue to recommend them49,50. As an alter-
native to these biologic agents MMF has been tested only in
uncontrolled series of patients, intolerant or refractory to
standard therapy with CYC51-53. The results are not brilliant,
but it must be emphasized that, due the severity of the renal
disease in most cases and the natural reluctance to use a
novel drug with uncertain efficacy, most of the studies have
examined the use of MMF in cases of relapse or resistance to
CYC therapy during the induction phase. In one of them,
conducted by Joy MS et al, 12 patients with relapsing disease
(n = 6) or non response (n = 6) to a course of 6 months of
CYC, received MMF 1-1,5 g twice daily, for a total of 24
weeks plus oral corticoids53. Only 10 patients completed 12
months of evaluation. MMF treatment was well tolerated,
with only transient effects related mostly to gastrointestinal
intolerance. In spite a good response, in what it concerns vas-
culitis disease activity with MMF therapy in 9 of the 10 final
patients evaluated, only a minority of these subjects achieved
a long-lasting remission (3/10). The other behaved like short
relapsers or poor responsers. The authors manifest the opi-
nion that MMF alone is unlikely to be an effective rescue
therapy for subjects resistant to induction therapy with CYC.
The other reports are also inconclusive about MMF benefit
to induce remission in ANCA-positive small vessel vasculi-
tis51,52. At the moment, there are underway 3 larger multicen-
ter prospective controlled studies (2 randomized) to evaluate
the efficacy of MMF in remission induction of ANCA-asso-
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ciated vasculitis when compared to CYC (NIH trials num-
bers NCT00103792, NCT00414128, NCT00405860). On the
background of the literature, and at the present time, data do-
esn’t support MMF use as first option therapy to induce re-
mission in ANCA associated vasculitis. 
REMISSION MAINTENANCE THERAPY
There is an important phase III controlled trial underway to
compare MMF to AZA in remission maintenance phase of
ANCA-positive small vessel vasculitis treatment after induc-
tion with CYC plus corticoids. This study is designed IM-
H. Oliveira Sá et al. Mycophenolate mofetil 
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Table I. Summary overview of the main clinical results of MMF randomized trials in Lupus Nephritis and IgA Neph-
ropathy
Author, year, reference N. of patients Mean follow-up Main efficacy and safety outcomes
Proliferative Lupus Nephritis
CR – Complete remission; PR – Partial remission; SCr- serum creatinine.
Chan TM et al 20006
(randomized)
Chan TM et al 200510
(randomized, extended
long-term study)
Ginzler EM et al 200512
(randomized)
Ong LM et al 200511
(randomized)
Contreras G et al 20049
(randomized)
IgA Nephropathy 
Chen X et al 2002, 
(randomized)38
Maes BD et al 2004
(randomized)39
Tang S at al 2005
(randomized)40





















CR: 16/21CYC oral/AZA; 17/21 MMF
PR: 3/21 CYC oral/AZA; 3/21 MMF
Death: 2/21 CYC oral/AZA; 0/21 MMF
Infections : 7/21 CYC oral/AZA; 4/21 MMF
MMF + prednisolone is as effective as CYC oral+ prednisolone followed by AZA in in-
ducing CR or PR and less toxic.
CR: 23/30 CYC oral/AZA; 24/32 MMF
PR: 7/30 CYC oral/AZA; 7/32 MMF
Death: 2/30 CYC oral/AZA; 0/32 MMF
Infections: 12/30 CYC oral/AZA; 4/32 MMF
MMF + prednisolone is more effective than CYC oral+prednisolone followed by AZA in
terms of renal and patient survival and less toxic.
CR: 4/69 iv CYC; 16/71 MMF
PR: 17/69 iv CYC; 21/71 MMF
Death: 2/69 iv CYC; 0/71 MMF
Infections: 68/75 iv CYC; 42/83 MMF
MMF is more effective than CYC pulse therapy in inducing remission and more safe. 
CR: 3/25 iv CYC; 5/19 MMF
PR: 10/25 iv CYC; 6/19 MMF
Death: 0/25 iv CYC; 0/19 MMF
Infections: 3/25 iv CYC; 3/19 MMF
MMF + corticosteroids is as effective and safer than CYC pulse therapy + corticoste-
roids as induction therapy.
CRF: 3/20 iv CYC; 1/20 MMF
Relapse-free survival: 12/20 iv CYC; 17/20 MMF
Death: 4/20 iv CYC; 1/20 MMF
Infections: 15/20 iv CYC; 6/20 MMF
Maintenance with MMF following short-term CYC induction is as effective and safer
than long-term CYC pulse therapy. 
Reduction of proteinuria at 12 months: MMF 0,8 ± 0,8 g/24 h; corticosteroids: 1,4 ±
1,6 g/24 h, p < 0,05)
Remission rate: MMF 44,1%; corticosteroids: 19,1%, p < 0,05
MMF is more efficacious in reducing proteinuria than prednisone.
MMF vs control (ACEIs + placebo)
No beneficial effect of MMF on renal function outcome or proteinuria.
Reduction of proteinuria by 50% or >: MMF 16/20; control (ACEIs, ARA): 6/20, 
p = 0,001
Rate of change of creatinine clearance: no difference MMF vs control (ACEIs,ARA)
MMF is effective in lowering proteinuria.
MMF vs control (ACEIs + placebo), mean baseline SCr 2,4 mg/dl
MMF not effective in reducing proteinuria nor modifying decrease of renal function in
patients who have already moderate renal insufficiency.
Nefrología (2008) 1, 82-92 87
PROVE trial (NIH trial NCT00307645) and will be conclu-
ded in 2008. A number of several therapeutic options had
been tried to get reasonable alternatives to CYC during the
maintenance phase of the treatment, avoiding relapses of di-
sease activity. Methotrexate is one of them but the results
were poor, first of all due to increased risk for malignancy45,48.
Azathioprine seems to be an alternative to sustained CYC
therapy after remission achievement on vasculitis ANCA-po-
sitive, based on data of the literature. In fact the Cyclophosp-
hamide versus Azathioprine for Remission in Generalized
Vasculitis trial (CYCAZAREM) conducted by EUVAS
Group, concluded that efficacy of AZA in combination with
steroids is identical to CYC’s for maintenance therapy, with
well tolerability54. 
Data about MMF efficacy for remission maintenance the-
rapy in ANCA vasculitis are based on uncontrolled studies
and case series. One of them, conducted by Langford CA et
al reported a good tolerability but a high frequency of relap-
ses (43% at 18 months of follow-up, n = 14)55. Another
study by Koukoulaki M et al, concerning 29 patients, rein-
forced the high rate of long-term relapses when using MMF
for remission maintenance in ANCA-associated vasculitis
with renal involvement. The mean duration of MMF therapy
was 20 months but 48,3% of patients relapsed at mean time
of 14 months52. Nowack R et al described, in opposite, a
small rate relapses with MMF use (1/11) although the period
of follow-up was shorter (15 months) and the number of pa-
tients smaller (n = 11)56. Another uncontrolled study using
MMF in relapsing or resistant ANCA-positive small vessel
vasculitis, demonstrated a sustained reduction in Birming-
han Vasculitis activity score in patients classified as disease
relapsers53. 
In summary, on the basis of current knowledge, for remis-
sion maintenance therapy in ANCA-positive small vessel vas-
culitis, AZA plus steroids seems a rationale choice to avoid
sustained CYC therapy. As MMF experience for maintenance
therapy is based on uncontrolled studies, we must wait until
larger controlled studies are finalized to clarify the beneficial
effects of MMF compared to AZA. 
PRIMARY FOCAL AND SEGMENTAL 
GLOMERULOSCLEROSIS (FSGS)
Primary FSGS is still a challenge to the nephrologist in
terms of diagnostic and treatment. As said by Alain Meyrier
in a recent review about this topic, FSGS is not a disease but
a lesion of obscure pathophysiology, with different variants
(tip, perihilar, cellular, collapsing and FSGS not otherwise
specified or NOS)57. The primary defect seems to concentra-
te on glomerular epithelial cell function like podocytes, alt-
hough in some types like collapsing variant of FSGS, parie-
tal epithelial cell role is crucial in the proliferative events. In
recent years, genetics of familial cases of FSGS have been
clarified, contributing to a better understanding of pathoge-
nesis of this common form of nephrotic syndrome (a po-
docytopathy with altered podocyte-specific proteins is com-
monly present: podocin/NPHS-2 gene, nephrin/NPHS-1
gene, α-actinin 4/ACTN4 gene, CD2AP protein and gene,
TRPC6 protein and gene, WT1 protein and gene)58. 
Corticosteroids, administrated in high doses and for a pro-
longed course (for 3 to 6 months), remain the mainstay of tre-
atment of primary FSGS. The best indicator of favorable
prognosis is proteinuria reduction59. Cytotoxic agents like
CYC and chlorambucil are specially indicated in case of ste-
roid-dependency. Steroid-resistance nephrotic syndrome re-
mains one of the leading causes of progression to end stage
renal disease in FSGS. Cyclosporine (CsA) is an important
therapeutic option in steroid resistant FSGS60. In pediatric po-
pulation, CsA seems to have the beneficial effect of being a
steroid-sparing agent, pushing a significant additional subsets
of child into remission61. Cyclosporine must be used in low
doses (lower than 5 mg/kg/day) associated with corticoste-
roids and for a prolonged course (frequently more than 18
months). The main problem with this kind of therapeutic is
CsA-dependency, even to a very low daily dosage (as 1
mg/kg/day).
MMF clinical experience in FSGS is resumed to a few
small uncontrolled studies and case series of patients with
no response to other therapies (steroid and cyclosporine re-
sistant) and with a short follow-up62-65. At the current time,
MMF use in FSGS remains totally empirical. Choi MJ et al
described MMF use in 18 patients with primary FGSG62. In-
dications for MMF treatment included steroid-resistance
and steroid or cyclosporine-dependency associated with
progressive renal insufficiency. Twelve of 18 patients recei-
ved concomitant steroid treatment. They observed total re-
mission in 2 patients and proteinuria reduction in 16. Corti-
costeroids were withdrawn completely in 8 of 12 patients.
Day CJ et al studied seven patients with frequent relapses
of nephrotic syndrome, despite treatment with CYC and/or
CsA; they were treated with MMF 1g twice daily together
with prednisolone63. Six patients went into complete remis-
sion and the seventh into partial remission. It must be emp-
hasized that in this group of patients, only 2 had FSGS
diagnostic on the renal biopsy, the others were diagnosed as
having minimal-change disease, which can partially ex-
plain the favorable results. Montané B et al treated nine
children and young adults with FSGS steroid resistance,
that had failed conventional treatment regimens with MMF
(250-500 mg/m2 per day)64. This drug, in association with
angiotensin blockade, was responsible for 72% reduction of
proteinuria below baseline after 6 months of follow-up and
this level was maintened for a minimum of 24 months of
observation. 
More recently, Cattran DC et al performed an open-label
6 months trial of MMF in 18 patients with corticosteroid-re-
sistant nephrotic syndrome. Of these 18 patients, 75% had
failed to respond to a cytotoxic and/or calcineurin inhibi-
tor65. They observed a substancial improvement in proteinu-
ria in 44% (8/18) of the patients by 6 months, although no
one had a complete remission and relapses were frequently
observed. 
Controlled trials are required to establish the role of MMF
on FSGS’s treatment. An important randomized, controlled
trial of FSGS is now occurring in the United States
(NCT00135811). This trial intends to compare two different
treatment regimens in biopsy-proven primary FSGS, namely
CsA versus MMF/pulse steroids and has as primary objective
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to determine whether treatment with MMF/pulse steroids is
superior to CsA in inducing remission from proteinuria over
12 months. The estimated number of patients being recruted
(n = 500) and the characteristics of the study are essencial for
our knowledge of MMF risk/benefit ratio on the treatment of
FSGS. 
MINIMAL-CHANGE DISEASE
Minimal-Change Disease is found mostly in pediatric popu-
lation (> 85% cases of nephrotic syndrome). In adults it ac-
counts for approximately 10 to 15% of idiopathic nephrotic
syndrome66. Minimal-Change Disease’s patognomonic le-
sion is the alteration of foot processes (effacement) that is
observed on electron microscopy. Although primary Mini-
mal-Change Disease has been described for decades, the
pathogenesis of this kind of injury remains unknown. There
are some hypothetic culprits that could explain the main his-
tological alterations. Some of the proposed mechanisms are
a cell circulating permeability factor like IL13, IL4 or the
macrophage migration inhibitory factor and more recently,
some oxygen species that could damage podocytes67-69. 
Oral glucocorticoids remain the standard therapy in both
adult and children Minimal-Change Disease. The steroid
response is generally good: complete remissions are com-
mon with only < 7% of children and approximately 12% of
adults being steroid-resistant. The problem is the elevated
rate of relapses or the high incidence of steroid-depen-
dency. Cyclophosphamide (2 mg/kg/day for 12 weeks) or
CsA (3-6 mg/kg/day) are two alternatives to these sub-
groups of patients70. Concerns about this kind of therapy
are the toxic adverse effects associated with these drugs,
particularly with CYC, and the very common cyclospori-
ne-dependency or cyclosporine-nephrotoxicity. This kind
of concern is bigger in pediatric population where both ste-
roid and CsA dependency compromise seriously the
growth and long-term renal survival. Persecuting the aim
of finding better alternatives to CYC and CsA in Minimal-
Change Disease, some uncontrolled observations suggest
that MMF therapy might have a beneficial role in the ma-
nagement of cases of steroid-dependency or steroid-resis-
tance, and would help obviate the need for CYC or CsA’s
use, particularly in pediatric population62,71-73. Most part of
the studies report to cases of steroid-dependency in chil-
dren and, all together, they include approximately 100 pa-
tients74-80. The doses of MMF differed between 180 and 600
mg/m2 body surface/dose twice daily. The findings in all of
those uncontrolled studies indicate that MMF is a useful
therapy in the treatment of patients with steroid-dependent
nephrotic syndrome and well tolerated. MMF therapy in
general, results in significant steroid or cyclosporine spa-
ring. The results in steroid-resistant nephrotic syndrome
were more disappointing78,79. 
Based on these encouraging preliminary observations in
steroid or CsA-dependency, mainly in pediatric population,
clinicians may choose to treat steroid-dependent children
early with MMF, avoiding the adverse effects of long term
steroid or cyclosporine therapy. Experience in adult steroid-
dependent or steroid-resistant nephrotic syndrome treated
with MMF is smaller, but still demonstrate similar clinical ef-
ficacy in steroid or cyclosporine sparing. 
In the meantime, we have to wait until controlled clinical
trials of MMF therapy in steroid dependent and steroid-resis-
tant nephrotic syndrome due to Minimal-Change Disease and
FSGS are available. 
MEMBRANOUS NEPHROPATHY 
As well as Minimal-Change disease is the most common
form of nephrotic syndrome in children, primary membra-
nous nephropathy (MN) still remains the most common
form of nephrotic syndrome in adults81. Membranous neph-
ropathy’s pathogenesis is associated to subepithelial depo-
sits (endogen or exogen unknown antigen) and secondary
activation of the complement with formation of the attack
complex in situ that damages the overlying podocytes. To
date, there is no MN’s treatment based precisely on the
known pathogenesis - as human trials with antiC5 (Eculizu-
mab) have been inconclusive82,83. As wisely mentioned by
Cattran DC, spontaneous remission occurs at a higher rate in
this disease than in other primary progressive nephropaties
(up to 30%)84. The high rate of spontaneous remission in this
disease, suggests an auto-regulated mechanism of injury and
repair, as long as the pathogenic process is not severe
enough, to promove irreversible lesions on the glomerular
structure and function. The other two thirds of patients that
did not develop spontaneous remission, show either persis-
tent proteinuria with long-term preservation of renal func-
tion or slow progression to renal failure85. These medium
and high-risk patients need usually to be treated with immu-
nosuppressive drugs that include alkylating agents together
with steroids for 6 months or cyclosporine and steroids for
6-12 months60,86,87. There is no evidence for benefit with im-
munosuppressive therapy for those with sub-nephrotic range
proteinuria, normal renal function or stage I or II disease on
renal biopsy84. The importance of reaching remission of
nephrotic syndrome in MN is overwhelming evident. Cat-
tran DC et al determined in a cohort of 350 patients with
nephrotic MN that 10 yr-renal survival was 100% in the
complete remission group, 90% in the partial remission
group and only 45% in the no remission group88. 
In spite of the MN treatment guidelines with cytotoxic
agents or cyclosporine, a recent well performed meta-
analysis of the different therapeutic classes (glucocorti-
coids alone, various alkylating agents with or without gli-
cocorticoids, calcineurin inhibitors either alone or with
glicocorticoids and finally azathioprine on the antimetabo-
lite class), that included 943 studies (only 18 randomized
controlled trials) involving 1,025 patients, failed to show
any long-term beneficial effect of any kind of treatment re-
gimen on patient or renal survival89. This meta-analysis pre-
cluded the use of glicocorticoids alone in nephrotic MN in
any case. 
New therapeutic agents in MN have to demonstrate the
contribute to ameliorate long-term renal survival besides the
ability to decrease proteinuria. 
Membranous nephropathy’s treatment with MMF has been
tried in several uncontrolled, nonrandomized trials that inclu-
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de problematic cases of steroid or cytotoxic resistance. In the
global, those uncontrolled studies report to 41 patients with a
follow-up between 8 and 9 months of MMF therapy. Choi MJ
et al used a median MMF range dose of 2 g/day and described
a median Up/c decrease from 7,3 to 1,5 (p = 0,0001) in 17 pa-
tients with steroid or cytotoxic resistant MN62. There were no
significant change of serum creatinine or mean arterial pres-
sure. Two patients of 17 achieved a complete remission. Mi-
ller G et al studied 16 nephrotic patients with MN treated for
a mean of 8 months (MMF dose range 0,5 to 2 g/day)90. Par-
tial remissions occurred in 2 of the 16 patients and 6 patients
experienced a halfing reduction of proteinuria. There were no
changes in mean serum creatinine. Polenakovic M et al stu-
died 8 patients with nephrotic MN treated for 9 months with
MMF and described a significant reduction of proteinuria
from 4,4 to 1,9 g/day91. 
There are two nonrandomized prospective trials with his-
toric controls and a follow-up of 12 months that aimed to
compare MMF treatment in MN with patients treated with
alkylating agents92,93. The first, described a significant and
comparable reduction in proteinuria in the MMF group rela-
ted to cytotoxic group but includes only 13 patients; the
other, more recent and including 32 patients, although de-
monstrating a decrease of proteinuria and improved renal
function with MMF therapy, wasn’t as effective nor better
tolerated than CYC therapy.
There is now underway a small controlled randomized
trial designed to compare MMF associated with prednisolo-
ne to clorambucil plus prednisolone in MN (NIH trial
NCT00404833). 
To date and facing those discouraging results about immu-
nosuppressive therapy in MN, including MMF, we might
share Remuzzi G hope that new and better agents that attack
the basic pathophysiology of MN are needed, namely therapy
that target B cells (e.g., rituximab)94 or synthetic ACTH95.
Further trials with this kind of biological agents acting as a
specific immunotherapy are required. 
OTHER GLOMERULAR DISEASES
There are a few references reporting MMF use in other primary
or secondary glomerular diseases characterized by macrophage
infiltration, overexpression of growth factors and proinflamma-
tory cytokines, increase in protein excretion and/or renal insuf-
ficiency. Some of these studies as in diabetes mellitus, subtotal
renal ablation syndrome and anti-membrane glomerular base-
ment membrane glomerulonephritis are experimental96-101. The
findings of these studies in rat models suggest a potential thera-
peutic role of MMF in the inhibition of glomerular inflamma-
tion and progression of renal histologic injury. There are ane-
doctal clinical reports about MMF use in patients with severe
glomerular pathology refractory to conventional therapies that
show some benefit on proteinuria remission and improvement
of renal function. One of them included patients with primary
membranoproliferative glomerulonephritis in which MMF
contributes to renal insufficiency resolution in 20% of the
cases102, the other reported a patient with Goodpasture’s syn-
drome refractory to conventional therapy that went into stable
remission with MMF therapy103. 
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